Pancreatic adenocarcinoma (PDAC) is a profoundly aggressive cancer form with a typically dismal prognosis, known for its frequent liver metastasis, which significantly affects patient survival rates. The propensity of PDAC to swiftly metastasize to the liver, even in early stages or post-radical surgical intervention, underscores the urgent need for a deeper comprehension of the fundamental mechanisms at play. This includes potential genetic mutations and signal transduction pathways. Moreover, the management of pancreatic cancer metastasis demands substantial focus and investigation. Even with the challenges presented by pancreatic cancer, researchers continue to gradually enhance our understanding and are steadily making progress in developing effective interventions.
This Research Topic aims to collect articles dedicated to enhancing therapeutic strategies and exploring potential molecular mechanisms related to pancreatic cancer, encompassing all forms of metastasis: liver, peritoneum, bone, and lung. An urgent need exists for the optimization of treatment strategies, which includes pharmaceutical interventions such as chemotherapy, targeted therapies, and immunotherapy, with an emphasis on evaluating their efficacy and toxicity. Likewise, localized treatments, like radiofrequency, microwave, and nanoknife therapies, in addition to surgical measures for oligometastases, require comprehensive refinement. Furthermore, our objective is to decipher the molecular mechanisms that instigate the occurrence of pancreatic cancer metastases, particularly focusing on liver metastases. We also hold a keen interest in the differences observed in metastases across various organs, namely the liver, lung, peritoneum, and bone. We welcome submissions covering but not limited to the following sub-topics:
1) Refinement of treatment strategies for pancreatic cancer metastases
2) Conversion surgery for pancreatic cancer with hepatic metastases
3) Localized treatment methodologies and their outcomes for PDAC metastases
4) Recent advancements in immunotherapy and targeted therapy for PDAC metastases, including potential beneficial patient populations
5) The underlying molecular mechanisms contributing to the occurrence of PDAC metastases, as well as the distinctive molecular pathways causing disparities among liver, lung, and peritoneal metastasis. Also, the possible mechanisms driving patient responses and treatment toxicities across varied treatments and the mechanisms fostering treatment resistance.
6) Studies on animal models and pre-clinical models of PDAC metastasis
7) Studies on searching for diagnostic markers for PDAC metastasis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Pancreatic adenocarcinoma (PDAC) is a profoundly aggressive cancer form with a typically dismal prognosis, known for its frequent liver metastasis, which significantly affects patient survival rates. The propensity of PDAC to swiftly metastasize to the liver, even in early stages or post-radical surgical intervention, underscores the urgent need for a deeper comprehension of the fundamental mechanisms at play. This includes potential genetic mutations and signal transduction pathways. Moreover, the management of pancreatic cancer metastasis demands substantial focus and investigation. Even with the challenges presented by pancreatic cancer, researchers continue to gradually enhance our understanding and are steadily making progress in developing effective interventions.
This Research Topic aims to collect articles dedicated to enhancing therapeutic strategies and exploring potential molecular mechanisms related to pancreatic cancer, encompassing all forms of metastasis: liver, peritoneum, bone, and lung. An urgent need exists for the optimization of treatment strategies, which includes pharmaceutical interventions such as chemotherapy, targeted therapies, and immunotherapy, with an emphasis on evaluating their efficacy and toxicity. Likewise, localized treatments, like radiofrequency, microwave, and nanoknife therapies, in addition to surgical measures for oligometastases, require comprehensive refinement. Furthermore, our objective is to decipher the molecular mechanisms that instigate the occurrence of pancreatic cancer metastases, particularly focusing on liver metastases. We also hold a keen interest in the differences observed in metastases across various organs, namely the liver, lung, peritoneum, and bone. We welcome submissions covering but not limited to the following sub-topics:
1) Refinement of treatment strategies for pancreatic cancer metastases
2) Conversion surgery for pancreatic cancer with hepatic metastases
3) Localized treatment methodologies and their outcomes for PDAC metastases
4) Recent advancements in immunotherapy and targeted therapy for PDAC metastases, including potential beneficial patient populations
5) The underlying molecular mechanisms contributing to the occurrence of PDAC metastases, as well as the distinctive molecular pathways causing disparities among liver, lung, and peritoneal metastasis. Also, the possible mechanisms driving patient responses and treatment toxicities across varied treatments and the mechanisms fostering treatment resistance.
6) Studies on animal models and pre-clinical models of PDAC metastasis
7) Studies on searching for diagnostic markers for PDAC metastasis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
